Aerovate climbs on all-stock merger deal with Jade

seekingalpha10-31

Maksim LabkouskiAerovate Therapeutics (NASDAQ:AVTE) added ~24% in the pre-market on Thursday after the company agreed to merge with privately held biotech Jade Biosciences in an all-stock transaction....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479082945?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-31 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479082945","market":"fut","top_or_hot":-1,"title":"Aerovate climbs on all-stock merger deal with Jade","media":"seekingalpha","content":"<div>\n<p>Maksim LabkouskiAerovate Therapeutics (NASDAQ:AVTE) added ~24% in the pre-market on Thursday after the company agreed to merge with privately held biotech Jade Biosciences in an all-stock transaction....</p>\n\n<a href=\"https://seekingalpha.com/news/4228395-aerovate-stock-rises-on-all-stock-merger-deal\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate climbs on all-stock merger deal with Jade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate climbs on all-stock merger deal with Jade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 20:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4228395-aerovate-stock-rises-on-all-stock-merger-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Maksim LabkouskiAerovate Therapeutics (NASDAQ:AVTE) added ~24% in the pre-market on Thursday after the company agreed to merge with privately held biotech Jade Biosciences in an all-stock transaction....</p>\n\n<a href=\"https://seekingalpha.com/news/4228395-aerovate-stock-rises-on-all-stock-merger-deal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4228395-aerovate-stock-rises-on-all-stock-merger-deal","article_id":"2479082945","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479082945","pubTimestamp":1730378822,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Maksim LabkouskiAerovate Therapeutics  added ~24% in the pre-market on Thursday after the company agreed to merge with privately held biotech Jade Biosciences in an all-stock transaction. Concurrently, a group of healthcare investors has agreed to bring in roughly $300M in gross proceeds as part of a private investment in Jade in support of the merger. The deal is expected to close in H1 2025. Per the terms, Aerovate  shareholders are expected to own nearly 2% of the combined entity, which will trade on Nasdaq under the ticker symbol “JBIO” and operate as Jade Biosciences under the leadership of Jade’s current CEO, Tom Frohlich. The combined entity is expected to focus on Jade’s pipeline of biologics which includes an experimental antibody therapy named JADE-001, targeted at the kidney disorder, IgA nephropathy.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SQQQ":"纳指三倍做空ETF","AVTE":"Aerovate Therapeutics, Inc.","BK4539":"次新股","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite"},"translate_title":"Aerovate与Jade达成全股票合并协议，股价攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.9,"AVTE":0.9,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Maksim LabkouskiAerovate Therapeutics (NASDAQ:AVTE) added ~24% in the pre-market on Thursday after the company agreed to merge with privately held biotech Jade Biosciences in an all-stock transaction. Concurrently, a group of healthcare investors has agreed to bring in roughly $300M in gross proceeds as part of a private investment in Jade in support of the merger. The deal is expected to close in H1 2025. Per the terms, Aerovate (NASDAQ:AVTE) shareholders are expected to own nearly 2% of the combined entity, which will trade on Nasdaq under the ticker symbol “JBIO” and operate as Jade Biosciences under the leadership of Jade’s current CEO, Tom Frohlich. The combined entity is expected to focus on Jade’s pipeline of biologics which includes an experimental antibody therapy named JADE-001, targeted at the kidney disorder, IgA nephropathy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479082945"}